2020
Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment
Borde T, Gaupp F, Geschwind JF, Savic LJ, Miszczuk M, Rexha I, Adam L, Walsh JJ, Huber S, Duncan JS, Peters DC, Sinusas A, Schlachter T, Gebauer B, Hyder F, Coman D, van Breugel JMM, Chapiro J. Idarubicin-Loaded ONCOZENE Drug-Eluting Bead Chemoembolization in a Rabbit Liver Tumor Model: Investigating Safety, Therapeutic Efficacy, and Effects on Tumor Microenvironment. Journal Of Vascular And Interventional Radiology 2020, 31: 1706-1716.e1. PMID: 32684417, PMCID: PMC7541537, DOI: 10.1016/j.jvir.2020.04.010.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibiotics, AntineoplasticBiosensing TechniquesCell Line, TumorCell ProliferationChemoembolization, TherapeuticDiffusion Magnetic Resonance ImagingHydrogen-Ion ConcentrationIdarubicinLiver Neoplasms, ExperimentalMaleMicrospheresMultidetector Computed TomographyParticle SizeRabbitsTumor MicroenvironmentConceptsMultiparametric magnetic resonanceRabbit liver tumor modelDiffusion-weighted imagingLiver tumor modelDEE chemoembolizationDrug-eluting embolic transarterial chemoembolizationTumor microenvironmentTumor modelMale New Zealand white rabbitsTumor acidosisNew Zealand white rabbitsVX2 liver tumorsZealand white rabbitsLaboratory parametersTransarterial chemoembolizationBead chemoembolizationMultiparametric MRDCE MR imagingLiver enzymesPostprocedural increaseIntratumoral hypoxiaLiver tumorsEntire lesionTherapeutic mechanismChemoembolization
2019
Prostatic Artery Embolization Using 100–300-μm Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up
Ayyagari R, Powell T, Staib L, Chapiro J, Raja A, Bhatia S, Chai T, Schoenberger S, Devito R. Prostatic Artery Embolization Using 100–300-μm Trisacryl Gelatin Microspheres to Treat Lower Urinary Tract Symptoms Attributable to Benign Prostatic Hyperplasia: A Single-Center Outcomes Analysis with Medium-Term Follow-up. Journal Of Vascular And Interventional Radiology 2019, 31: 99-107. PMID: 31771896, DOI: 10.1016/j.jvir.2019.08.005.Peer-Reviewed Original ResearchMeSH KeywordsAcrylic ResinsAge FactorsAgedAged, 80 and overComorbidityCone-Beam Computed TomographyConnecticutEmbolization, TherapeuticGelatinHumansLower Urinary Tract SymptomsMaleMiddle AgedOrgan SizeParticle SizeProstateProstatic HyperplasiaQuality of LifeRecovery of FunctionRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeConceptsInternational Prostate Symptom ScoreLower urinary tract symptomsPost-void residualCharlson Comorbidity IndexProstatic artery embolizationProstate gland volumeMedian lobe enlargementBenign prostatic hyperplasiaTrisacryl gelatin microspheresArtery embolizationProstatic hyperplasiaGland volumeAdverse event recordingMedical therapy failureClavien-Dindo classificationProstate Symptom ScoreMedium-term followUrinary tract symptomsLower urinary tractMedium-term outcomesPost-procedure valuesQuality of lifeComorbidity indexTract symptomsConsecutive patients